Interpace Biosciences Reports Quarterly Results for June 30, 2026

What Happened
Interpace Biosciences, Inc. (IDXG) filed a Form 8‑K on August 12, 2026 (Item 2.02) to announce its results of operations and financial condition for the quarter ended June 30, 2026. The company issued a press release dated August 10, 2026 reporting the quarterly results; the full text of that press release is attached to the 8‑K as Exhibit 99.1 and is incorporated by reference.

Key Details

• Form 8‑K filed on August 12, 2026 under Item 2.02 (Results of Operations and Financial Condition).
• Press release announcing quarterly results dated August 10, 2026, included as Exhibit 99.1.
• Reporting period: quarter ended June 30, 2026 (quarterly results / earnings disclosure).
• Cover page Interactive XBRL file included (Exhibit 104).

Why It Matters
This filing notifies investors that Interpace has publicly released its quarterly earnings and financial condition for the period ended June 30, 2026. Retail investors should read the attached press release for the company’s reported revenue, earnings (or loss), cash position, and any management commentary or guidance that could affect valuation or near‑term trading. The 8‑K itself references the press release but does not restate the financial figures — consult Exhibit 99.1 for the detailed numbers.